Trial · NCT01670565
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Modified Rodnan Skin Score (MRSS) | Mycophenolate Mofetil + Belimumab | -10 | Inter-Quartile Range -13 to -9 | units on a scale | |
| Change in Modified Rodnan Skin Score (MRSS) | Mycophenolate Mofetil + Saline (Placebo) | -3.0 | Inter-Quartile Range -15 to -1 | units on a scale | |
| Number of Adverse Events and Serious Adverse Events | Mycophenolate Mofetil + Belimumab | Total number of AEs | 53 | number of AEs | |
| Number of Adverse Events and Serious Adverse Events | Mycophenolate Mofetil + Saline (Placebo) | Total number of AEs | 56 | number of AEs | |
| Number of Adverse Events and Serious Adverse Events | Mycophenolate Mofetil + Belimumab | Total number of infectious AEs | 18 | number of AEs | |
| Number of Adverse Events and Serious Adverse Events | Mycophenolate Mofetil + Saline (Placebo) | Total number of infectious AEs | 16 | number of AEs | |
| Number of Adverse Events and Serious Adverse Events | Mycophenolate Mofetil + Belimumab | Serious AEs | 0 | number of AEs | |
| Number of Adverse Events and Serious Adverse Events | Mycophenolate Mofetil + Saline (Placebo) | Serious AEs | 3 | number of AEs | |
| Change in Forced Vital Capacity (FVC) | Mycophenolate Mofetil + Belimumab | 5.00 | Inter-Quartile Range 0.00 to 8.00 | % predicted | |
| Change in Forced Vital Capacity (FVC) | Mycophenolate Mofetil + Saline (Placebo) | -2.00 | Inter-Quartile Range -6.00 to 4.00 | % predicted | |
| Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) | Mycophenolate Mofetil + Belimumab | 2.00 | Inter-Quartile Range -7.00 to 7.00 | % predicted | |
| Change in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) | Mycophenolate Mofetil + Saline (Placebo) | 0.00 | Inter-Quartile Range -6.00 to 7.00 | % predicted | |
| Change in Scleroderma Health Assessment Questionnaire Disability Index (SHAQ DI) | Mycophenolate Mofetil + Belimumab | -0.25 | Inter-Quartile Range -0.38 to -0.25 | score on a scale | |
| Change in Scleroderma Health Assessment Questionnaire Disability Index (SHAQ DI) | Mycophenolate Mofetil + Saline (Placebo) | 0.00 | Inter-Quartile Range -0.13 to 0.13 | score on a scale | |
| Change in in Short Form-36 (SF-36) Questionnaire:Mental Component Summary | Mycophenolate Mofetil + Belimumab | 7.50 | Inter-Quartile Range 2.50 to 18.50 | score on a scale | |
| Change in in Short Form-36 (SF-36) Questionnaire:Mental Component Summary | Mycophenolate Mofetil + Saline (Placebo) | 3.00 | Inter-Quartile Range 0.00 to 10.00 | score on a scale | |
| Change in Short Form-36 (SF-36) Questionnaire: Physical Component Summary | Mycophenolate Mofetil + Belimumab | 8.00 | Inter-Quartile Range -3.50 to 19.00 | scores on a scale, 0-100 | |
| Change in Short Form-36 (SF-36) Questionnaire: Physical Component Summary | Mycophenolate Mofetil + Saline (Placebo) | -3.00 | Inter-Quartile Range -3.00 to 27.00 | scores on a scale, 0-100 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01670565/results